We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205769

CAS#: 80841-48-1 (isethionate)

Description: Asulacrine, also known as CI-921; NSC-343499; SN-21407, is the isethionate salt of an amsacrine analogue with antineoplastic properties. Asulacrine inhibits the enzyme topoisomerase ll, thereby blocking DNA replication and RNA and protein synthesis.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-08-03. Prices are subject to change without notice.

Amsalog, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 205769
Name: Amsalog
CAS#: 80841-48-1 (isethionate)
Chemical Formula: C26H30N4O7S2
Exact Mass:
Molecular Weight: 574.669
Elemental Analysis: C, 54.34; H, 5.26; N, 9.75; O, 19.49; S, 11.16

Synonym: Amsalog; Asulacrine isethionate; CI921; CI-921; CI 921; NSC-343499; SN-21407; NSC343499; SN21407.

IUPAC/Chemical Name: 9-((2-methoxy-4-(methylsulfonamido)phenyl)amino)-N,5-dimethylacridine-4-carboxamide ethanesulfonate


InChi Code: InChI=1S/C24H24N4O4S.C2H6O3S/c1-14-7-5-8-16-21(14)27-23-17(9-6-10-18(23)24(29)25-2)22(16)26-19-12-11-15(13-20(19)32-3)28-33(4,30)31;1-2-6(3,4)5/h5-13,28H,1-4H3,(H,25,29)(H,26,27);2H2,1H3,(H,3,4,5)

SMILES Code: O=C(C1=CC=CC2=C(NC3=CC=C(NS(=O)(C)=O)C=C3OC)C4=CC=CC(C)=C4N=C12)NC.CCS(=O)(O)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Additional Information

Related CAS#
80841-47-0 (Asulacrine)
80841-48-1 (Asulacrine isethionate)


1: Fyfe D, Raynaud F, Langley RE, Newell DR, Halbert G, Gardner C, Clayton K, Woll PJ, Judson I, Carmichael J. A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. Cancer Chemother Pharmacol. 2002 Jan;49(1):1-6. PubMed PMID: 11855748.

2: Fyfe D, Price C, Langley RE, Pagonis C, Houghton J, Osborne L, Woll PJ, Gardner C, Baguley BC, Carmichael J; Cancer Research Campaing Phase I/II Trials Committee. A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule. Cancer Chemother Pharmacol. 2001 Apr;47(4):333-7. PubMed PMID: 11345650.

3: Elliott W, Howard C, Roberts B, Hook K, Vincent P, Corbett T, Leopold W. Enhanced therapeutic effect of amsalog (CI-921) in combination with cisplatin in vitro and in vivo. Oncol Rep. 1996 Nov;3(6):1153-9. PubMed PMID: 21594529.

4: Sklarin NT, Wiernik PH, Grove WR, Benson L, Mittelman A, Maroun JA, Stewart JA, Robert F, Doroshow JH, Rosen PJ, et al. A phase II trial of CI-921 in advanced malignancies. Invest New Drugs. 1992 Nov;10(4):309-12. PubMed PMID: 1487405.

5: Robertson IG, Palmer BD, Paxton JW, Shaw GJ. Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse. Xenobiotica. 1992 Jun;22(6):657-69. PubMed PMID: 1441589.

6: Henck JW, Brown SL, Anderson JA. Developmental toxicity of CI-921, an anilinoacridine antitumor agent. Fundam Appl Toxicol. 1992 Feb;18(2):211-20. PubMed PMID: 1601220.

7: Harvey VJ, Hardy JR, Smith S, Grove W, Baguley BC. Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer. Eur J Cancer. 1991;27(12):1617-20. PubMed PMID: 1664218.

8: Paxton JW, Kim SN, Whitfield LR. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. Cancer Res. 1990 May 1;50(9):2692-7. PubMed PMID: 2328494.

9: Kestell P, Paxton JW, Evans PC, Young D, Jurlina JL, Robertson IG, Baguley BC. Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. Cancer Res. 1990 Feb 1;50(3):503-8. PubMed PMID: 2297692.

10: Ching LM, Finlay GJ, Joseph WR, Baguley BC. Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells. Eur J Cancer. 1990 Jan;26(1):49-54. PubMed PMID: 2138478.